Global IPO markets made steady gains in 2024, with IPO proceeds increasing compared to the previous year as the high interest ...

Cocoa extract supplementation among older adults had no effect overall on the occurrence of age-related macular degeneration ...

Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...

The Global Smoking Cessation and Nicotine De-Addiction Products Market is valued at approximately USD 24.54 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 10.77% ...

Kotak Alternate Asset Managers have announced an investment of ₹1,050 crore in Tirupati Medicare Ltd, a contract development ...

Haleon has named Nathalie Gerschtein as president North America, following Lisa Paley’s announcement to step down from her ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

The pharma is spending $2.5 billion on an R&D center in Beijing. Elsewhere, Adaptimmune warned it could run out of cash and Pfizer sold its remaining stake in Haleon.

A roundup of the latest health news includes Yemen's malnutrition crisis, potential CDC leadership changes, the role of medical visas in regional diplomacy, and drug industry dynamics. Notable ...

Per a previous share buyback plan, Pfizer sold around 44.14 million shares worth approximately $220 million (£170 million) directly to Haleon. Haleon was a consumer health joint venture (JV), an ...

The disposal represents Pfizer's exit from its investment in Haleon, which originated from a JV formed with GSK in 2019.